Is alternate day dosing of oral iron an effective option for iron-deficiency anaemia?

Kaundal R, Bhatia P, Jain A, et al. Randomized controlled trial of twice-daily versus alternate-day oral iron therapy in the treatment of iron-deficiency anemia. Ann Hematol.

Dapagliflozin in people with chronic kidney disease.

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Dapagliflozin in patients with chronic kidney disease. 2020;383:1436-46. Dr Teck Khong, DTB Associate Editor, Clinical Pharmacology, St George's, University of London, UK.

What does the TIME study tell us about morning and evening dosing of antihypertensive medication?

Mackenzie IS, Rogers A, Poulter NR, Cardiovascular outcomes in adults with hypertension with evening vs morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. 2022;400:1417-25.

Evidence for empagliflozin in heart failure with preserved ejection fraction (HFpEF).

Anker SD, Butler J, Filippatos G, Empagliflozin in heart failure with a preserved ejection fraction. , 2021; 385:1451-61.

Short-term effect of deprescribing antihypertensives in older people.

Sheppard JP, Burt J, Lown M, Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: The OPTIMISE randomized clinical trial. 2020;323:2039-51. Dr Teck Khong, DTB Associate Editor, Clinical Pharmacology, St George's, University of London, UK.

Treating hypertension with a pill containing very low doses of four antihypertensive agents compared with standard dose irbesartan.

Chow CK, Atkins ER, Hillis GS, Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. 2021;398:1043-52. Dr Teck Khong, DTB Associate Editor Clinical Pharmacology, St George's, University of London, UK.

What role for PCI in stable ischaemic heart disease?

Maron DJ, Hochman JS, Reynolds HR, Initial Invasive or Conservative Strategy for Stable Coronary Disease. 2020;382:1395-1407. Dr Teck Khong, DTB Associate Editor Clinical Pharmacology, St George's, University of London, UK.

Effect of dapagliflozin in patients with heart failure.

McMurray JJV, Solomon SD, Inzucchi SE, Dapagliflozin in patients with heart failure and reduced ejection fraction. 2019;381:1995-2008. Dr Joshua Au Yeunga, Clinical Pharmacology, St Thomas' Hospital, London, UK and Dr Teck Khong, Clinical Pharmacology, St George's, University of London, UK.

Effect of PCI of culprit and non-culprit lesions for patients with STEMI compared with culprit lesion-only PCI.

Mehta SR, Wood DA, Storey RF, Complete Revascularization with Multivessel PCI for Myocardial Infarction. 2019; 381:1411-21. Dr Emma Magavern and Dr Teck Khong Clinical Pharmacology, St George's, University of London, UK.

Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes.

Wiviott SD, Raz I, Bonaca MP, Dapagliflozin and cardiovascular outcomes in type 2 diabetes. 2019;380:347-57. Dr Emma Magavern and Dr Teck Khong Clinical Pharmacology, St George's, University of London, UK Dr Teck Khong, DTB Associate Editor Clinical Pharmacology, St George's, University of London, UK.

Moderate calorie restriction improves cardiometabolic risk factors in healthy individuals.

Dr James Kimpton and Dr Teck Khong Clinical Pharmacology, St George's, University of London, UK Dr Teck Khong, DTB Associate Editor Clinical Pharmacology, St George's, University of London, UK Kraus WE, Bhapkar M, Huffman KM, 2 years of calorie restriction and cardiometabolic (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial. 2019; 7: 673-83.

Is tramadol associated with an increase in all-cause mortality among patients with osteoarthritis?

Zeng C, Dubreuil M, LaRochelle MR, Association of tramadol with all-cause mortality among patients with osteoarthritis. 2019;321:969-82 Dr Catrin Page and Dr Teck Khong Clinical Pharmacology, St George's, University of London, UK Dr Teck Khong, DTB Associate Editor Clinical Pharmacology, St George's, University of London, London, UK.

Prescribing of anticholinergic medicines to patients initiating dementia medicines.

Narayan SW, Pearson SA, Litchfield M, Anticholinergic medicines use among older adults before and after initiating dementia medicines. 2019;85:1957-1963. Dr Christopher JD Threapleton and Dr Teck Khong, Clinical Pharmacology, St George's, University of London, UK Dr Teck Khong, DTB Associate Editor, Clinical Pharmacology, St George's, University of London, London, UK.

No benefit from amitriptyline for chronic low back pain?

DTB commentaries provide an overview of, and commentary on, a clinical trial, systematic review or observational study.